tafasitamab


( Last Updated : November 25, 2021)
Generic Name:
tafasitamab
Project Status:
Received
Therapeutic Area:
Diffuse large B-cell lymphoma (DLBCL)
Manufacturer:
Incyte Biosciences Canada Corporation
Call for patient/clinician input open:
Brand Name:
Minjuvi
Project Line:
Reimbursement Review
Project Number:
PC0266-000
Call for patient/clinician input closed:
Tumour Type:
Lymphoma
NOC Status at Filing:
Post NOC

Details


Manufacturer Requested Reimbursement Criteria1:
In combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, who are not eligible for autologous stem cell transplant (ASCT).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Tafasitamab is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, who are not eligible for autologous stem cell transplant (ASCT).
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones

Call for patient/clinician input open October 15, 2021
Call for patient/clinician input closed December 09, 2021
Submission received November 19, 2021
Submission accepted